Pharming CEO Fabrice Chouraqui Resigns After Disagreement on Direction
Dow Jones
Sep 29
Pharming Group has parted ways with its top executive, Fabrice Chouraqui, after a disagreement over the biotechnology company's strategy.
Pharming on Tuesday said Chouraqui has stepped down as chief executive and executive director by mutual agreement with the board after concluding that their views on how to advance the Netherlands-based company's strategy aren't sufficiently aligned.
Pharming said Leverne Marsh, its chief commercial officer, and Kenneth Lynard, its finance chief, have stepped in as interim co-CEOs, with Marsh leading patient-focused operations and Lynard heading global corporate functions.
Pharming said its board has started a formal search for a permanent successor to Chouraqui, who had been at the helm since March 2025.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.